National Pension Service Buys 12,647 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

National Pension Service grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.3% in the third quarter, Holdings Channel reports. The fund owned 185,972 shares of the company’s stock after acquiring an additional 12,647 shares during the quarter. National Pension Service’s holdings in IDEXX Laboratories were worth $93,957,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of IDXX. Crewe Advisors LLC bought a new position in shares of IDEXX Laboratories during the 1st quarter valued at approximately $26,000. Ridgewood Investments LLC bought a new position in IDEXX Laboratories in the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC bought a new position in IDEXX Laboratories in the 2nd quarter worth approximately $28,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its holdings in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares during the period. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on IDXX shares. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Piper Sandler reissued a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday. BTIG Research assumed coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $415.98 on Wednesday. The firm’s fifty day moving average price is $476.04 and its 200-day moving average price is $486.32. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The stock has a market cap of $34.24 billion, a P/E ratio of 40.11, a price-to-earnings-growth ratio of 3.64 and a beta of 1.36. IDEXX Laboratories, Inc. has a fifty-two week low of $404.74 and a fifty-two week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the company posted $2.53 EPS. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.